Prevalence of COVID-19 in patients with parkinson's disease and the impact of parkinson's disease on COVID-19 prognosis.

IF 2.1 4区 医学 Q3 CLINICAL NEUROLOGY
Demet Yildiz, Nilüfer Büyükkoyuncu Pekel, Melih Yüksel, Aksel Özdemir, Ebru Çetin Kenan, Muhammed Furkan Öztürkci
{"title":"Prevalence of COVID-19 in patients with parkinson's disease and the impact of parkinson's disease on COVID-19 prognosis.","authors":"Demet Yildiz, Nilüfer Büyükkoyuncu Pekel, Melih Yüksel, Aksel Özdemir, Ebru Çetin Kenan, Muhammed Furkan Öztürkci","doi":"10.1007/s13760-025-02888-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to retrospectively evaluate the prevalence of COVID-19 infection among patients with Parkinson's disease (PD), along with the clinical course and factors associated with mortality.</p><p><strong>Methods: </strong>A total of 1,786 patients diagnosed with Parkinson's disease and registered at our hospital were screened. Among these, 222 had undergone PCR testing for COVID-19, of whom 76 tested negative and 152 tested positive, indicating a COVID-19 prevalence of 8.51% in the PD population. Due to insufficient data, 63 of the COVID-19 positive patients were excluded. The final study cohort included 177 patients: 89 patients with PD (50.3%) and 88 age- and sex-matched controls (49.7%). Clinical, laboratory, and prognostic parameters were compared between groups.</p><p><strong>Results: </strong>The prevalence of dementia was significantly higher in the PD group. Mortality at both 28 and 90 days was also significantly increased among patients with PD. Notably, those receiving combined therapy with dopamine agonists and levodopa had lower mortality rates at both time points. In patients who died within 28 or 90 days, levels of age, neutrophil count, lymphocyte count, D-dimer, ferritin, C-reactive protein (CRP), and troponin differed significantly compared to survivors.</p><p><strong>Conclusion: </strong>Patients with Parkinson's disease represent a vulnerable population at increased risk for adverse outcomes from COVID-19. Close clinical monitoring, continuous dopaminergic treatment, and a personalized approach are essential for optimizing management during COVID-19 infection.</p>","PeriodicalId":7042,"journal":{"name":"Acta neurologica Belgica","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta neurologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13760-025-02888-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to retrospectively evaluate the prevalence of COVID-19 infection among patients with Parkinson's disease (PD), along with the clinical course and factors associated with mortality.

Methods: A total of 1,786 patients diagnosed with Parkinson's disease and registered at our hospital were screened. Among these, 222 had undergone PCR testing for COVID-19, of whom 76 tested negative and 152 tested positive, indicating a COVID-19 prevalence of 8.51% in the PD population. Due to insufficient data, 63 of the COVID-19 positive patients were excluded. The final study cohort included 177 patients: 89 patients with PD (50.3%) and 88 age- and sex-matched controls (49.7%). Clinical, laboratory, and prognostic parameters were compared between groups.

Results: The prevalence of dementia was significantly higher in the PD group. Mortality at both 28 and 90 days was also significantly increased among patients with PD. Notably, those receiving combined therapy with dopamine agonists and levodopa had lower mortality rates at both time points. In patients who died within 28 or 90 days, levels of age, neutrophil count, lymphocyte count, D-dimer, ferritin, C-reactive protein (CRP), and troponin differed significantly compared to survivors.

Conclusion: Patients with Parkinson's disease represent a vulnerable population at increased risk for adverse outcomes from COVID-19. Close clinical monitoring, continuous dopaminergic treatment, and a personalized approach are essential for optimizing management during COVID-19 infection.

帕金森病患者COVID-19患病率及帕金森病对COVID-19预后的影响
目的:本研究旨在回顾性评估帕金森病(PD)患者中COVID-19感染的患病率、临床病程以及与死亡率相关的因素。方法:对我院登记的1786例帕金森病患者进行筛查。其中,222人接受新冠病毒PCR检测,其中76人阴性,152人阳性,PD人群中新冠病毒感染率为8.51%。由于资料不足,排除了63例COVID-19阳性患者。最终的研究队列包括177例患者:89例PD患者(50.3%)和88例年龄和性别匹配的对照组(49.7%)。比较两组间的临床、实验室和预后参数。结果:PD组痴呆患病率明显增高。PD患者28天和90天的死亡率也显著增加。值得注意的是,接受多巴胺激动剂和左旋多巴联合治疗的患者在两个时间点的死亡率都较低。在28天或90天内死亡的患者中,年龄、中性粒细胞计数、淋巴细胞计数、d -二聚体、铁蛋白、c反应蛋白(CRP)和肌钙蛋白水平与幸存者相比有显著差异。结论:帕金森病患者是COVID-19不良后果风险增加的弱势群体。密切的临床监测、持续的多巴胺能治疗和个性化方法对于优化COVID-19感染期间的管理至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta neurologica Belgica
Acta neurologica Belgica 医学-临床神经学
CiteScore
4.20
自引率
3.70%
发文量
300
审稿时长
6-12 weeks
期刊介绍: Peer-reviewed and published quarterly, Acta Neurologica Belgicapresents original articles in the clinical and basic neurosciences, and also reports the proceedings and the abstracts of the scientific meetings of the different partner societies. The contents include commentaries, editorials, review articles, case reports, neuro-images of interest, book reviews and letters to the editor. Acta Neurologica Belgica is the official journal of the following national societies: Belgian Neurological Society Belgian Society for Neuroscience Belgian Society of Clinical Neurophysiology Belgian Pediatric Neurology Society Belgian Study Group of Multiple Sclerosis Belgian Stroke Council Belgian Headache Society Belgian Study Group of Neuropathology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信